Teva Pharmaceutical Industries Ltd (ADR)  

(Public, NYSE:TEVA)   Watch this stock  
Find more results for TEVA
18.61
+1.31 (7.54%)
After Hours: 18.41 -0.20 (-1.09%)
Dec 15, 5:47PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 17.50 - 18.70
52 week 10.85 - 38.31
Open 17.81
Vol / Avg. 66.12M/31.50M
Mkt cap 19.65B
P/E     -
Div/yield 0.09/4.57
EPS -5.87
Shares 1.02B
Beta 0.55
Inst. own 56%
Feb 12, 2018
Q4 2017 Teva Pharmaceutical Industries Ltd Earnings Release (Estimated) - 7:00AM EST - Add to calendar
Dec 14, 2017
Teva Pharmaceutical Industries Ltd to Discuss Restructuring Plan and Additional Measures to Improve Its Business and Financial Performance Conference Call - Webcast
Nov 2, 2017
Q3 2017 Teva Pharmaceutical Industries Ltd Earnings Call - Webcast
Nov 2, 2017
Q3 2017 Teva Pharmaceutical Industries Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 10.93% 1.38%
Operating margin 6.74% 5.80%
EBITD margin - 30.72%
Return on average assets 2.85% 0.41%
Return on average equity 8.60% 0.24%
Employees 56,960 -
CDP Score - A-

Address

5 Basel St., P.O. Box 3190
PETAH TIKVA, 49131
Israel
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Officers and directors

Sol J. Barer Ph.D. Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Kaare Schultz President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Michael McClellan Chief Financial Officer, Executive Vice President
Bio & Compensation  - Reuters
Dipankar Bhattacharjee President and Chief Executive Officer-Global Generic Medicines Group
Age: 56
Bio & Compensation  - Reuters
Robert Koremans President & Chief Executive Officer-Global Specialty Medicines
Age: 55
Bio & Compensation  - Reuters
Iris Beck-Codner Executive Vice President - Global Brand & Communications
Age: 52
Bio & Compensation  - Reuters
Richard Daniell Executive Vice President - European Commercial
Bio & Compensation  - Reuters
Carlo de Notaristefani Executive Vice President - Global Operations
Age: 59
Bio & Compensation  - Reuters
Sven Dethlefs Ph.D. Executive Vice President - Global Marketing & Portfolio
Bio & Compensation  - Reuters
Hafrun Fridriksdottir Executive Vice President - Global R&D
Age: 55
Bio & Compensation  - Reuters